Menu
Recruiting NCT06711562

Model-informed Individualized Treatment of Anti-infective Drugs

— Observational Osteoarticular Infections

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Anti-Infective Drugs.
Who it may be relevant to
Registry conditions: Osteoarticular Infections. Basic parameters: No limits · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Model-informed Individualized Treatment of Anti-infective Drugs in Patients With Osteoarticular Infections

Overview

The study aims to optimize individualized treatment of anti-infective drugs in osteoarticular infections by analyzing drug exposure in patients blood and/or tissues using population pharmacokinetics.

Interventions

  • Drug Anti-Infective Drugs
    Anti-infective drugs are administered using the traditional clinical dosing regimen, with no interventions.

Primary outcome measures

  • Clearance (L/h) [Time frame: Through study completion, an average of 30 days]
  • Volume of Distribution (L) [Time frame: Through study completion, an average of 30 days]
Secondary outcome measures (3)
  • ratio of the area under the concentration-time curve from 0 to 24 hours [Time frame: Through study completion, an average of 30 days]
  • erythrocyte sedimentation rate [Time frame: Through study completion, an average of 30 days]
  • Adverse events [Time frame: Through study completion, an average of 30 days]

Eligibility criteria

Inclusion criteria

  • Patients with suspected/confirmed osteoarticular infections who are undergoing anti-infective drug therapy.

Exclusion criteria

  • Pregnant/lactating women.
  • There are other factors that the researchers think are not suitable for inclusion.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

China · 1 center
  • Shandong Public Health Clinical Center — Jinan

Identifiers

NCT: NCT06711562 · SDU-2024-BJ-005

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗